Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis

Zheng-Xiao Zhao; Lin-Wei Lu; Jian Qiu; Qiu-Ping Li; Fei Xu; Bao-Jun Liu; Jing-Cheng Dong; Wei-Yi Gong

doi:10.18632/oncotarget.18964

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis

Zheng-Xiao Zhao, Lin-Wei Lu, Jian Qiu, Qiu-Ping Li, Fei Xu, Bao-Jun Liu, Jing-Cheng Dong and Wei-Yi Gong _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:2728-2738. https://doi.org/10.18632/oncotarget.18964

Metrics: PDF 1755 views | HTML 2676 views | ?

Abstract

Zheng-Xiao Zhao1,2, Lin-Wei Lu1,2, Jian Qiu1,2, Qiu-Ping Li1,2, Fei Xu1,2, Bao-Jun Liu1,2, Jing-Cheng Dong1,2 and Wei-Yi Gong1,2

1Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China

2The Academy of Integrative Medicine of Fudan University, Shanghai 200032, P.R. China

Correspondence to:

Wei-Yi Gong, email: [email protected]

Keywords: Glucose transporter-1, GLUT-1, cancer, prognosis, meta-analysis

Received: February 23, 2017 Accepted: June 18, 2017 Published: July 04, 2017

ABSTRACT

Objective: Glucose transporter-1 (GLUT-1) as the major glucose transporter present in human cells is found overexpressed in a proportion of human malignancies. This meta-analysis is attempted to assess the prognostic significance of GLUT-1 for survival in various cancers.

Materials and Methods: We conducted an electronic search using the databases PubMed, Embase and Web of Science, from inception to Oct 20th, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.

Results: Fourty-one studies with a total of 4794 patients were included. High GLUT-1 expression was significantly associated with poorer prognosis [overall survival: HR = 1.833 (95% CI: 1.597–2.069, P < 0.0001); disease-free survival: HR = 1.838 (95% CI: 1.264–2.673, P < 0.0001); progression-free survival: HR = 2.451 (95% CI: 1.668–3.233, P < 0.0001); disease specific survival: HR = 1.96 (95% CI: 1.05–2.871, P < 0.0001)].

Conclusions: High GLUT-1 expression may be an independent prognostic marker to predict poor survival in various types of cancers. Further clinical trials with high quality need to be conducted to confirm our conclusion.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18964

Publication Alerts

Meta-Analysis:

Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis

Abstract